Treating Locally Advanced Head and Neck Malignant Tumor With Anlotinib and Chemoradiotherapy
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Head and neck tumors include well-differentiated squamous cell carcinoma, adenocarcinoma,
adenoid cystic carcinoma, small cell carcinoma, sarcoma, olfactory blastoma, and
mucoepidermoid carcinoma, which are highly invasive and have a high rate of recurrence and
metastasis. For tumors that cannot be radically removed at the local advanced stage, even
after traditional comprehensive treatment, survival is still very low. Therefore, we need to
explore new treatment methods to achieve tumor degeneration and increase the surgical
resection rate or control local lesions to improve the survival rate of tumors. According to
previous research reports and clinical exploration, anlotinib has evidence support for the
treatment of locally advanced head and neck tumors. With a considerable effect in the early
stage, we tried to initially observe the clinical treatment efficiency, toxic and side
effects, progression-free survival time, overall survival time and quality of life of
anlotinib in the treatment of patients with refractory head and neck carcinoma. Provide
patients with a more optimal treatment plan and improve survival.